Inflazome Announces Acquisition by Roche
21.9.2020 09:00:00 EEST | Business Wire | Press release
Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones.
Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The company is a leader in the development of inflammasome inhibitors.
The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.
Matt Cooper, Chief Executive Officer, Inflazome, commented: “We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”
Manus Rogan, Chairman and co-founding investor of Inflazome, said: “It has been a privilege to work alongside Matt, his team and my co-investors. The Company, which was established just four years ago, developed a portfolio of clinical and pre-clinical molecules with a lean, highly experienced team and limited invested capital.”
Lazard acted as financial advisor and Goodwin Procter and Byrne Wallace acted as legal counsel to Inflazome.
About Inflazome
Inflazome is a biotech company leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes. Inflammasomes are understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH. Inflazome has a portfolio of orally available small molecule NLRP3 inhibitors, with lead molecules having successfully completed Phase I clinical trials, as well as several high potential earlier-stage programmes.
Inflazome has raised €55m in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund.
Inflazome is headquartered in Dublin, Ireland.
About the NLRP3 Inflammasome
Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/
Contact information
Inflazome
Dr Jeremy Skillington | VP Business Development
E: j.skillington@inflazome.com
Media:
FTI Consulting
UK & International | Ciara Martin/Tim Stamper
T: +44 20 37271000
Ireland & International | Jonathan Neilan/Patrick Berkery
T: +353 86 602 5988
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 20:03:00 EEST | Press release
Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoint, demonstrating non-inferiority
Tigo Energy Improves Installer Choice via Fronius Compatibility with TS4 Product Line22.10.2026 19:02:00 EEST | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a manufacturer declaration of compatibility from Fronius International GmbH, documenting compatibility between Tigo Flex MLPE products and multiple Fronius inverter families. The letter covers Tigo TS4-A-F, TS4-A-2F, TS4-A-O, and TS4-X-O products and the Fronius Primo GEN24, Primo GEN24 208-240, Symo GEN24, Verto, Tauro, and Tauro ECO inverter families, when configured according to the requirements specified by Fronius and Tigo. Building on established compatibility in Europe, the declaration extends manufacturer-confirmed compatibility to markets worldwide, including the United States and Canada, giving solar professionals greater flexibility to design high-quality systems using manufacturer-confirmed technology combinations. Fronius develops solar technologies and solutions for residential, commercial, and large-scale applications, with a port
Saudi Maritime & Logistics Congress Highlights Maritime Sector Integration and Opportunities for Trade and Investment Growth in the Kingdom22.10.2026 17:52:00 EEST | Press release
The Saudi Maritime & Logistics Congress highlighted Saudi Arabia’s role in supporting the continuity of trade flows and strengthening supply chain resilience as it opened at Jeddah Superdome, bringing together representatives of government entities, maritime transport and logistics leaders, and the business community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022362613/en/ The Congress takes place as rapid changes in trade and shipping prompt companies to reassess transport routes and operational and investment choices. It provides a platform for dialogue among stakeholders to explore opportunities for cooperation and strengthen integration between ports and maritime, land transport and logistics services, supporting operational efficiency and supply chain reliability. In his opening address, His Excellency Eng. Fawaz Alsahli, President of the Transport General Authority in Saudi Arabia, emphasised that the Kingdom’s
Ministerial Roundtable Discusses Mobilising Green Investments for a Resilient and Inclusive Global Economy22.10.2026 17:49:00 EEST | Press release
HE Saeed Mohammed Al Tayer, Chairman of the World Green Economy Organization, opened the Ministerial Roundtable titled "From Ambition to Bankable Action-Mobilising Green Investments for a Resilient and Inclusive Global Economy," during the 12th World Green Economy Summit (WGES), held on 21-22 October 2026 at the Dubai World Trade Centre under the theme "From Success to Scale: Showcasing the Green Economy." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022803264/en/ Ministerial Roundtable Discusses Mobilising Green Investments for a Resilient and Inclusive Global Economy (Photo: AETOSWire) The session was attended by HE Dr. Amna bint Abdullah Al Dahak, Minister of Climate Change and Environment, the United Arab Emirates; HE Aliou Gori Diouf, Minister of Environment and Ecological Transition, Senegal; HE Balarabe Abbas Lawal, Minister of Environment, Nigeria; HE Steven Victor, Minister of Agriculture, Fisheries, and the En
Andersen Consulting Adds Collaborating Firm TechSparq22.10.2026 16:30:00 EEST | Press release
Andersen Consulting broadens its technology and business transformation capabilities through a Collaboration Agreement with TechSparq, a U.S.-based firm that combines strategy, commerce engineering, and AI with hands-on implementation. TechSparq is a digital consulting firm providing strategy and advisory, commerce engineering, and AI and agentic commerce services to organizations across retail and consumer goods, luxury and fashion, and eCommerce and direct-to-consumer markets. Headquartered in Oregon, the firm combines strategic planning with hands-on delivery to help clients advance digital initiatives, customer experience, and operating models. “We built our firm to close the gap between the people who develop the strategy and the people responsible for making it work,” said Dedrick Boyd, founder and CEO of TechSparq. “Our collaboration with Andersen Consulting gives us an opportunity to bring that execution-focused model to a broader range of organizations while combining our appr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom